Genmab A/S (GMAB) and G1 Therapeutics Inc. (NASDAQ:GTHX) Comparison side by side

We are comparing Genmab A/S (NASDAQ:GMAB) and G1 Therapeutics Inc. (NASDAQ:GTHX) on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genmab A/S 23 0.00 642.32M 0.00 0.00
G1 Therapeutics Inc. 25 0.00 27.91M -2.97 0.00

Demonstrates Genmab A/S and G1 Therapeutics Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Genmab A/S 2,837,102,473.50% 0% 0%
G1 Therapeutics Inc. 110,403,481.01% -34.3% -32.4%

Analyst Recommendations

The table given features the ratings and recommendations for Genmab A/S and G1 Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Genmab A/S 0 0 3 3.00
G1 Therapeutics Inc. 0 0 1 3.00

Genmab A/S has a 9.75% upside potential and a consensus price target of $25.33. Competitively the average price target of G1 Therapeutics Inc. is $45, which is potential 81.31% upside. Based on the results given earlier, G1 Therapeutics Inc. is looking more favorable than Genmab A/S, analysts view.

Institutional & Insider Ownership

Institutional investors owned 0% of Genmab A/S shares and 97.3% of G1 Therapeutics Inc. shares. Comparatively, G1 Therapeutics Inc. has 17.81% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Genmab A/S 1.67% 8.38% 15.82% 33.09% 53.95% 44.46%
G1 Therapeutics Inc. 6.02% 0.17% -36.46% 23.05% -34.44% 19.58%

For the past year Genmab A/S was more bullish than G1 Therapeutics Inc.

Summary

Genmab A/S beats on 7 of the 10 factors G1 Therapeutics Inc.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.